RxDoctor Payments Data

Dorwoah Counts

Family · Columbia, SCNPI 1205020237

Payments from drug & device makers

$2,253in general payments, 2019–2025

Across 86 payments — averaging $26.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$570
  • Novo Nordisk$259
  • Abbott$207
  • Esperion Therapeutics, Inc.$206
  • Novartis$122
  • Lilly USA, LLC$108
  • plus $781 from 22 others

What the payments were for

  • Food & beverage$2,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,253 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab80$68,036
FarxigaDapagliflozin Propanediol51$57,686
OzempicSemaglutide57$55,083
Repatha PushtronexEvolocumab39$29,837
MounjaroTirzepatide23$23,973
JardianceEmpagliflozin14$20,847
LinzessLinaclotide22$14,920
EliquisApixaban18$11,125
Humalog Kwikpen U-200Insulin Lispro11$3,800
Amlodipine-AtorvastatinAmlodipine/Atorvastatin11$3,257
Humalog Kwikpen U-100Insulin Lispro13$2,556
Lidocaine24$2,450
Rosuvastatin Calcium75$2,018
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,852
Ezetimibe47$1,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$570$57,68651 claims
Novo NordiskOzempic$259$55,08357 claims
Lilly USA, LLCMounjaro$108$23,97323 claims
Boehringer IngelheimJardiance$79$20,84714 claims
PfizerEliquis$47$11,12518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →